BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Seagen Inc.
Eli Lilly and Company
Pfizer
RemeGen Co., Ltd.
Amgen
Debiopharm International SA
Pfizer
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Amgen
AstraZeneca
Eli Lilly and Company
Janssen Research & Development, LLC
Eli Lilly and Company
Boehringer Ingelheim
National Institutes of Health Clinical Center (CC)
AstraZeneca
Rutgers, The State University of New Jersey
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
BioNTech SE
Tesaro, Inc.
AbbVie
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
Zai Lab (Hong Kong), Ltd.
AbbVie
RayzeBio, Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Jemincare
Peking University Cancer Hospital & Institute
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Daiichi Sankyo
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Thomas Jefferson University
Inspirna, Inc.
Amgen
UNC Lineberger Comprehensive Cancer Center
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Blueprint Medicines Corporation
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
Sichuan University
Arcus Biosciences, Inc.
Eli Lilly and Company
Taiho Pharmaceutical Co., Ltd.